Literature DB >> 15849371

Update of the Drug Resistance Mutations in HIV-1: 2005.

Victoria A Johnson1, Francoise Brun-Vezinet, Bonaventura Clotet, Brian Conway, Daniel R Kuritzkes, Deenan Pillay, Jonathan Schapiro, Amalio Telenti, Douglas Richman.   

Abstract

Since 2000, the International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group has worked as an independent entity and forged a collaborative process to identify key HIV-1 drug resistance mutations. The goal of the group is to quickly deliver accurate and unbiased information to clinical practitioners on HIV-1 resistance. This April 2005 version of the IAS-USA Drug Resistance Mutations Figures replaces the version published in this journal in October 2004. The IAS-USA Drug Resistance Mutations Figures are designed for use in identifying mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Care should be taken when using this list of mutations for surveillance or epidemilogic studies of transmission of drug-resistant virus. A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15849371

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  27 in total

1.  Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

Authors:  Marine Karchava; Wendy Pulver; Lou Smith; Sean Philpott; Timothy J Sullivan; Judith Wethers; Monica M Parker
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

Review 2.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

3.  Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

Authors:  Florence Doualla-Bell; Ava Avalos; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Ndwapi Ndwapi; Vladimir A Novitsky; Bluma Brenner; Maureen Oliveira; Daniella Moisi; Howard Moffat; Ibou Thior; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Authors:  Roger Paredes; Vincent C Marconi; Thomas B Campbell; Daniel R Kuritzkes
Journal:  J Virol Methods       Date:  2007-07-26       Impact factor: 2.014

5.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

Review 6.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

7.  Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.

Authors:  Lin Liu; Susanne May; Douglas D Richman; Frederick M Hecht; Martin Markowitz; Eric S Daar; Jean-Pierre Routy; Joseph B Margolick; Ann C Collier; Christopher H Woelk; Susan J Little; Davey M Smith
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

8.  Mapping noncovalent ligand binding to stemloop domains of the HIV-1 packaging signal by tandem mass spectrometry.

Authors:  Kevin B Turner; Nathan A Hagan; Andrew S Kohlway; Daniele Fabris
Journal:  J Am Soc Mass Spectrom       Date:  2006-07-26       Impact factor: 3.109

9.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

Review 10.  Oral complications of HIV disease.

Authors:  Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.